Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10643552 | 0.84 | MEN1 (0.48) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL10644355 | 0.84 | MEN1 (0.51) | MEN1PABPC1KMT2ACA12CA1 | |
| Mitozolomide SCHEMBL97695 | 0.83 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL25600791 | 0.82 | MEN1 (0.44) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3336603 | 0.82 | MEN1 (0.47) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL31452009 | 0.82 | MEN1 (0.42) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL26321492 | 0.81 | MEN1 (0.43) | MEN1PABPC1KMT2ACA12CA1 | |
| Water SCHEMBL10648619 | 0.81 | MEN1 (0.46) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL10646065 | 0.81 | MEN1 (0.69) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL25434387 | 0.81 | MEN1 (0.42) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | claimed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | claimed |
| EP-3116507-B1 | COMPOUNDS FOR ORAL TREATMENT OF BRAIN TUMORS | KADMON CORP LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| WO-2009083042-A1 | METHODS AND MEANS FOR THE TREATMENT OF CANCER | VAN TELLINGEN OLAF (NL) | 2009-07-09 | — | — | WO | disclosed |
| US-20090170880-A1 | Methods and Means for the Treatment of Cancer | VAN TELLINGEN OLAF | 2009-07-02 | — | — | US | disclosed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | MEN1 766/4885PABPC1 916/4885KMT2A 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.